Bio-Techne reports Q2 adjusted EPS 42c, consensus 38c

Reports Q2 revenue $297.03M, consensus $285.42M. “The Bio-Techne (TECH) team once again executed at a high level and delivered strong second quarter results,” said Kim Kelderman, president and CEO of Bio-Techne. “It is encouraging to see early signs of improvement in the biopharma end-market, which was evident in our cell and gene therapy and protein analysis instrumentation businesses. We delivered this top-line result with a continued focus on profitability, which resulted in a 30.1% adjusted operating margin, an increase of 110 basis points sequentially.”